Literature DB >> 9420760

Factors influencing myocardial salvage with primary angioplasty.

J H O'Keefe1, C L Grines, M A DeWood, T M Bateman, T F Christian, R J Gibbons.   

Abstract

BACKGROUND: The purpose of this study was to evaluate the factors influencing the salvage of jeopardized myocardium in patients treated with primary angioplasty for acute myocardial infarction. METHODS AND
RESULTS: This multicenter study involved 59 patients with acute myocardial infarction who underwent primary angioplasty without antecedent thrombolytic therapy and paired baseline (before angioplasty) and predischarge tomographic perfusion imaging by quantitative 99mTc-labeled sestamibi techniques for assessing the initial area at risk and eventual infarct size. Of the 59 patients who underwent primary angioplasty, Thrombolysis In Myocardial Infarction (TIMI) level 3 perfusion was restored in the infarct vessel in 54 patients (92%). On average, approximately one third of the left ventricular myocardial mass was initially jeopardized by the infarction in progress; eventual infarct size was 18% +/- 15% of the left ventricle; myocardial salvage was 16% +/- 17% of the left ventricle. Primary angioplasty salvaged 46% +/- 50% of initially jeopardized myocardium. Factors correlated with myocardial salvage included elapsed time from onset of pain to reperfusion, infarct location (anterior infarcts had more myocardial salvage than inferior infarcts), and residual flow to the infarct zone at preangioplasty baseline levels. In the five patients reperfused less than 2 hours from onset of pain, 80% of the jeopardized myocardium was salvaged. Myocardial salvage beyond 2 hours was much more variable.
CONCLUSIONS: Primary angioplasty was highly effective at restoring normal perfusion in the infarct vessel and salvaging jeopardized myocardium. The myocardial salvage was highly variable and correlated with elapsed time to reperfusion, baseline residual flow to the infarct zone, and infarct location.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9420760     DOI: 10.1016/s1071-3581(05)80006-6

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  35 in total

1.  Determinants of infarct size in reperfusion therapy for acute myocardial infarction.

Authors:  T F Christian; R S Schwartz; R J Gibbons
Journal:  Circulation       Date:  1992-07       Impact factor: 29.690

2.  In vitro validation of a simple tomographic technique for estimation of percentage myocardium at risk using methoxyisobutyl isonitrile technetium 99m (sestamibi).

Authors:  M K O'Connor; T Hammell; R J Gibbons
Journal:  Eur J Nucl Med       Date:  1990

3.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Authors:  J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

4.  Primary angioplasty for acute myocardial infarction in 1,000 consecutive patients. Results in an unselected population and high-risk subgroups.

Authors:  J H O'Keefe; W L Bailey; B D Rutherford; G O Hartzler
Journal:  Am J Cardiol       Date:  1993-12-16       Impact factor: 2.778

5.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

6.  Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial.

Authors:  W D Weaver; M Cerqueira; A P Hallstrom; P E Litwin; J S Martin; P J Kudenchuk; M Eisenberg
Journal:  JAMA       Date:  1993-09-08       Impact factor: 56.272

7.  Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups.

Authors:  R J Gibbons; D R Holmes; G S Reeder; K R Bailey; M R Hopfenspirger; B J Gersh
Journal:  N Engl J Med       Date:  1993-03-11       Impact factor: 91.245

8.  Risk stratification and survival after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1983-08-11       Impact factor: 91.245

9.  Noninvasive identification of myocardium at risk in patients with acute myocardial infarction and nondiagnostic electrocardiograms with technetium-99m-Sestamibi.

Authors:  T F Christian; I P Clements; R J Gibbons
Journal:  Circulation       Date:  1991-05       Impact factor: 29.690

10.  Effect of infarct location on myocardial salvage assessed by technetium-99m isonitrile.

Authors:  T F Christian; R J Gibbons; B J Gersh
Journal:  J Am Coll Cardiol       Date:  1991-05       Impact factor: 24.094

View more
  5 in total

1.  Outcome of medical versus invasive treatment strategies for non-high-risk ischemic heart disease.

Authors:  J H O'Keefe; T M Bateman; R W Ligon; J Case; J Cullom; C Barnhart; J Spertus
Journal:  J Nucl Cardiol       Date:  1998 Jan-Feb       Impact factor: 5.952

Review 2.  What is the current status of quantification and nuclear medicine in cardiology?

Authors:  G Hör
Journal:  Eur J Nucl Med       Date:  1996-07

3.  Acute and chronic administration of disodium disuccinate astaxanthin (Cardax) produces marked cardioprotection in dog hearts.

Authors:  Garrett J Gross; Samuel F Lockwood
Journal:  Mol Cell Biochem       Date:  2005-04       Impact factor: 3.396

4.  The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. For the CORE investigators (Collaborative Organisation for RheothRx Evaluation).

Authors:  P Chareonthaitawee; R J Gibbons; R S Roberts; T F Christian; R Burns; S Yusuf
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

5.  Increased pulse wave transit time after percutaneous coronary intervention procedure in CAD patients.

Authors:  Lizhen Ji; Chengyu Liu; Peng Li; Xinpei Wang; Changchun Liu; Yinglong Hou
Journal:  Sci Rep       Date:  2018-01-08       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.